SecBot SecBot
PRESS-RELEASE ·Filed Nov 4, 2026

STE

STERIS plc
BULLISH
Impact 6/10
Horizonweeks Processed12d 4h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The raised guidance and strong Life Sciences performance are the key positives. Monitor the Xodus Medical acquisition closing and its impact on the full-year outlook, as well as the restructuring plan's execution and savings realization timeline.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$254.12
T+0 close · Nov 4, 2026 · via day close
Latest settled
−0.27%
T+5 · $253.44 · next T+20 in 17d
Vs SPY
−3.56%
α at T+5
Latest observation
+5.99%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $254.12entry
  2. T+1 · 11d ago −0.72%α −1.03% · $252.30
  3. T+5 · 5d ago −0.27%α −3.56% · $253.44
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

STERIS reported fiscal Q2 2027 adjusted EPS of $2.94, beating the $2.68 consensus by 9.7%, and revenue of $1.6B (+9% YoY) vs. $1.56B consensus. The company raised its full-year adjusted EPS guidance to $11.35-$11.55 from $11.10-$11.30, citing solid underlying demand and ~$0.18 benefit from tariff refunds. Life Sciences revenue grew 18% and guidance for that segment was raised, while Healthcare and AST met expectations.

Key Financial Metrics

EPS (Adj.)
$2.94
est $2.68 · +9.7% · GAAP: $2.19
Revenue
$1.6B
est $1.6B · +2.6% · +9.0% YoY
Rating
beat
Guidance
7-8% as reported growth
raised
Free Cash Flow
$492.5M

Key Facts

  • Adjusted EPS $2.94 vs. consensus $2.68 (beat by 9.7%)
  • Revenue $1.6B vs. consensus $1.56B (beat by 2.6%)
  • Revenue +9% YoY; constant currency organic revenue +8%
  • FY2027 adjusted EPS guidance raised to $11.35-$11.55 from $11.10-$11.30
  • Life Sciences segment revenue +18% YoY; segment guidance raised to 9-10% from 6-7%
  • Tariff refunds contributed ~$0.18 to the guidance increase
  • New restructuring plan with ~$45M total charges, ~$9M annualized savings
  • Free cash flow for H1 FY2027 was $492.5M vs. $527.7M prior year

Financial Impact

Adjusted EPS beat consensus by $0.26 (9.7%); revenue beat by ~$40M (2.6%); FY guidance raised by $0.25 at midpoint

revenueepsguidancefree cash flow

Segment Breakdown

SegmentRevenueGrowth
Healthcare$1.1B+9.0%
Applied Sterilization Technologies$295.6M+5.0%
Life Sciences$170.6M+18.0%

Risk Factors

  • Free cash flow declined 6.7% in H1 due to working capital timing
  • Restructuring charges of ~$45M may weigh on near-term reported results
  • Tariff refund benefit is non-recurring and may not repeat
  • Healthcare segment operating income growth lagged revenue growth due to inflation and investments

Market Snapshot

Exchange
NYSE
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Analyst Consensus
69% bullish (13 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3395890

Track record

21 reports on STE

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Entry $264.32 Now $264.32 +0.00% settles Nov 23
  2. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $264.32 Now $264.32 +0.00% settles Nov 20
  3. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $264.32 Now $264.32 +0.00% settles Nov 20
  4. Nov 12, 20264d ago 144 Neutral 2/10 Entry $253.44 Now $264.32 +4.29% settles Nov 19
  5. Nov 10, 20266d ago 144 Neutral 2/10 Entry $256.27 Now $264.32 +3.14% settles Nov 18
  6. Nov 4, 202612d ago 8-K Neutral 4/10 Entry $254.12 to $253.44 Now $264.32 +4.01% ▼ −0.27% −3.56% vs SPY
  7. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  8. Nov 4, 202612d ago Press Release Bullish 6/10 Viewing Entry $254.12 to $253.44 Now $264.32 +4.01% ▼ −0.27% −3.56% vs SPY
  9. Oct 28, 202619d ago Press Release Neutral 2/10 Entry $232.14 to $254.12 Now $264.32 +13.86% ▲ +9.47% +14.19% vs SPY
  10. Oct 20, 202627d ago Press Release Neutral 1/10 Entry $221.48 to $228.49 Now $264.32 +19.34% ▲ +3.17% +3.61% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (12h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026